Exome Sequencing and Molecular Profiling in Patients with Hidradenitis Suppurativa (HS)

Published: 19-09-2024 Last updated: 18-01-2025

To Identify genetic variants and clinical phenotypes associated with risk of HS and to characterize the key cellular and molecular mechanisms and pathways involved in the pathogenesis of moderate-to-severe HS.

Ethical review	Approved WMO
Status	Pending
Health condition type	Skin appendage conditions
Study type	Observational invasive

Summary

ID

NL-OMON57185

Source ToetsingOnline

Brief title HSProGen

Condition

• Skin appendage conditions

Synonym

acne ectopica, Hidradenitis Suppurativa

Research involving Human

Sponsors and support

Primary sponsor: The European Hidradenitis Supurativa Foundation (EHSF) e.V. **Source(s) of monetary or material Support:** Regeneron,The European Hidradenitis Supurativa Foundation (EHSF) e.V.

1 - Exome Sequencing and Molecular Profiling in Patients with Hidradenitis Suppurati ... 6-05-2025

Intervention

Keyword: exome sequencing, molecular profiling

Outcome measures

Primary outcome

Whole-exome sequencing and/or array genotyping to identify single variants

and/or gene-based burden tests significantly associated with HS status and

severity.

Secondary outcome

Transcriptional profiling through bulk RNA sequencing.

Study description

Background summary

Despite some progress in understanding and treating Hidradenitis suppurativa (HS), significant improvements in therapeutic options will require a better understanding of HS pathophysiology, particularly the underlying genetic variants that may serve as important drivers of the disease.

Study objective

To Identify genetic variants and clinical phenotypes associated with risk of HS and to characterize the key cellular and molecular mechanisms and pathways involved in the pathogenesis of moderate-to-severe HS.

Study design

An exploratory observational study as part of a Europe wide consortium.

Study burden and risks

All research data will be handled in accordance with the Dutch Data Protection Act and privacy regulations of Erasmus MC. Extra time during the visit is required from participants as they need to fill out a questionnaire and more information is needed from the physician. Furthermore, a swap and (optional) blood sample is collected. Risks are minimal. A buccal swap is a non-invasive method. Venepuncture has a small risk for pain, minor bleeding, and/or hematoma. The patient will not directly benefit from this research, but participation contributes to increased knowledge about HS and subsequently improving treatment and care.

Contacts

Public The European Hidradenitis Supurativa Foundation (EHSF) e.V.

Auenweg 38 Dessau 06847 DE **Scientific** The European Hidradenitis Supurativa Foundation (EHSF) e.V.

Auenweg 38 Dessau 06847 DE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

- Male or female, age 18 years or older at the screening visit
- Patients must have a diagnosis of HS (in compliance with Dessau criteria as modified in San Francisco) for at least one year (365 days) prior the screening visit
- HS lesions must be present in at least two distinct classical anatomic areas
 - 3 Exome Sequencing and Molecular Profiling in Patients with Hidradenitis Suppurati ... 6-05-2025

(e.g., left and right axilla; or left axilla and left inguino-crural fold)

- Willing and able to comply with clinic visits and study-related procedures
 Provide informed consent signed by study patient or legally acceptable
- representative
- Able to understand and complete study-related material

Exclusion criteria

- Presence of skin comorbidities (e.g. inverse psoriasis, epidermal inclusion cyst) that may interfere with study assessments for HS

- Severe concomitant illness(es)
- Pregnant or breastfeeding women

Study design

Design

Study type: Observational invasive		
Masking:	Open (masking not used)	
Control:	Uncontrolled	
Primary purpose:	Basic science	

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	15-10-2024
Enrollment:	400
Туре:	Anticipated

Ethics review

Approved WMO	
Date:	19-09-2024
Application type:	First submission
Review commission:	METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

4 - Exome Sequencing and Molecular Profiling in Patients with Hidradenitis Suppurati ... 6-05-2025

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register CCMO **ID** NL84959.078.23